GABAA receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment

被引:98
|
作者
Ströhle, A
Romeo, E
di Michele, F
Pasini, A
Yassouridis, A
Holsboer, F
Rupprecht, R
机构
[1] Max Planck Inst Psychiat, D-80804 Munich, Germany
[2] Univ Roma Tor Vergata, IRCCS Santa Lucia, Rome, Italy
来源
AMERICAN JOURNAL OF PSYCHIATRY | 2002年 / 159卷 / 01期
关键词
D O I
10.1176/appi.ajp.159.1.145
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Previous studies have shown that neuroactive steroids modulate anxiety and stress reactivity. However, no data on the possible role of these gamma-aminobutyric acid(A) (GABA(A)) receptor-modulating neuroactive steroids in patients with anxiety disorders are available. Method: The concentrations of 3alpha,5alpha-tetrahydroprogesterone (3alpha,5alpha-THP), 3alpha,5beta-THP, 3beta,5alpha-THP, and their precursors were studied in the plasma of 10 patients with panic disorder and 10 matched healthy comparison subjects. In addition, the effects of paroxetine treatment on neuroactive Steroid concentrations were studied in the panic disorder patients over a 24-week period. Results: Unexpectedly, patients with panic disorder had significantly greater concentrations of the positive allosteric modulators 3alpha,5alpha-THP and 3alpha,5beta-THP and significantly lower concentrations of 3beta,5alpha-THP (a functional antagonist for GABAA agonistic steroids), which might result in greater GABA(A) receptor-mediated neuronal activity. Paroxetine treatment did not affect neuroactive steroid concentrations, which were highly stable over 24 weeks. Conclusions. Differences in neuroactive steroid composition in patients with panic disorder were the opposite of those seen in patients with major depression and may reflect counter-regulative mechanisms against the occurrence of spontaneous panic attacks.
引用
收藏
页码:145 / 147
页数:3
相关论文
共 50 条
  • [1] Neuroactive steroid levels in patients with panic disorder
    Murphy, BEP
    AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (03): : 593 - 594
  • [2] Induced panic attacks shift γ-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder preliminary results
    Ströhle, A
    Romeo, E
    di Michele, F
    Pasini, A
    Hermann, B
    Gajewsky, G
    Holsboer, F
    Rupprecht, R
    ARCHIVES OF GENERAL PSYCHIATRY, 2003, 60 (02) : 161 - 168
  • [3] Plasma catecholamine levels before and after paroxetine treatment in patients with panic disorder
    Oh, Jae-Young
    Yu, Bum-Hee
    Heo, Jung-Yoon
    Yoo, Ikki
    Song, Hyemin
    Jeon, Hong Jin
    PSYCHIATRY RESEARCH, 2015, 225 (03) : 471 - 475
  • [4] Involvement of GABAA receptor modulating neuroactive steroids in patients with social phobia
    Laufer, N
    Maayan, R
    Hermesh, H
    Marom, S
    Gilad, R
    Strous, R
    Weizman, A
    PSYCHIATRY RESEARCH, 2005, 137 (1-2) : 131 - 136
  • [5] ROLE OF GABAA RECEPTOR-MODULATING NEUROSTEROIDS DURING THE EPILEPTOGENESIS IN THE PARIETAL CORTEX OF THE EPILEPTIC MUTANT EL
    Murashima, Y.
    Yoshii, M.
    EPILEPSIA, 2009, 50 : 69 - 69
  • [6] Influences of treatment with paroxetine on cholesterol levels in patients with panic disorder
    Kim, EJ
    Yu, B
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S370 - S370
  • [7] Neuroactive steroid levels in patients with panic disorder -: Dr. Strohle and colleagues reply
    Ströhle, A
    Romeo, E
    di Michele, F
    Pasini, A
    Yassouridis, A
    Holsboer, F
    Rupprecht, R
    AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (03): : 594 - 594
  • [8] Basal metabolism in panic patients during a treatment with paroxetine
    Bertani, A
    Liperi, L
    Bussi, R
    Perna, G
    Bellodi, L
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S570 - S571
  • [9] Increased cholesterol levels after paroxetine treatment in patients with panic disorder
    Kim, EJ
    Yu, BH
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (06) : 597 - 599
  • [10] Platelet serotonin function after paroxetine treatment in patients with panic disorder
    Yu, B. -H.
    Kang, E. -H.
    Shim, H. -B.
    Park, J. -E.
    Lee, I. -S.
    Kim, K. -J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 283 - 284